Canada Markets closed

DiaMedica Therapeutics Inc. (DMA.V)

YHD - YHD Delayed Price. Currency in USD
Add to watchlist
500,000.00+1.16 (+0.00%)
At close: 06:07PM EDT
Sign in to post a message.
  • x
    x
    DMAC has third party validation on DM199 comparison to human and animal KLK1. Furthermore, there were a lot of research done in Asia on KLK1 before it was approved for stroke. Its worth the risk in my opinion.
  • R
    Rocket man
    So much animal data. So much human urine derived klk1 data from China and porcine form data from Japan.

    Klk1 is not only used for scite stroke treatment and prevention, it’s also used for CKD, acute renal failure, diabetic retinal disease, migraine headaches, ischemic limb issues, and has even been investigated for men with low sperm counts. There are decades of data.

    Stroke and stroke prevention market is huge. But it’s just the beginning !!!!
  • R
    Ron
    Nothing but good news from this Quarter update. Don’t worry about the price, low volume, with a line up trying to get in at these rock bottom prices.
  • R
    Rocket man
    Big conference call next week.

    Update for dm199 stroke. Number of sites and patients

    ?partnerships in Asia Europe US

    Any news for partnerships for renal ?

    Any update on the other product Dm300 ?

    If people understood the potential for this with stroke and kidney disease This should be 30 by now
  • c
    chevies
    Two new study sites, Indiana and Virginia, not yet on the website map.
  • D
    David
    THIS WILL TRADE ..AT .0025 CENTS. WATCH AND YOU SHALL SEE
  • R
    Ron
    Interest rate hikes threaten again. And again, this company is flush with cash to carry it through 2024. Don’t be fooled into selling, buy more!
  • D
    Daniel
    Despite being 47 years old, David still dwells in his mothers basement. I guess you can refer to him as a Cellar Dweller. Its because he cannot be trusted to stay the course taking his medicine. Mommy needs to keep a constant eye on him to ensure he indeed is taking his pills 3x daily.
  • x
    x
    Only 16K volume, the market maker can't make much money on the spread between the bid and ask.
  • R
    Ron
    Look at the volumes. Nobody wants to sell. That’s a long term good sign
  • D
    David
    LOVING THE LIQUIDATION VOLUME!
  • R
    Rocket man
    They can’t be happy now. Nor are any of the stockholders. It’s curious that the price is not higher given multibillion potential return for stroke treatment alone in a relatively short time. Not to even mention stroke prevention.
    Further Kidney disease is still on the table and We would hope for some type of announcement soon for phase three trials for at least two of the three ckd cohorts. Need a partnership I’m sure but that would drive stock price way up
    The other unknown is their other product. Not much has been said but that should hold some value if it’s legit
  • c
    chevies
    Up to 11 study sites for Remedy 2. We’re on a roll. Go Diamedica!
  • D
    David
    BUY AS MANY $5 PUTS AS YOU CAN ...ASAP....
  • R
    Ron
    Load up, these low prices won’t last!
  • R
    Ron
    On sale!
  • D
    Daniel
    $DMAC is a $20 stock in this calendar year 💯
  • c
    chevies
    I just checked the website, now up to 9 study sites!
  • D
    David
    THIS COMPANY WILL NOT ONLY NEVER SEE $3 AGAIN. BUT ONCE IT BREAKS $2...1.25 COMES QUICK..AND THEN .81 CENTS WHICH IVE CLAIMED ALL ALONG